688351 Shanghai Microport Ep Medtech
- 22.49
- -0.01-0.04%
Shanghai Microport Ep Medtech News
Microelectrophysiology (688351): Maintaining a high growth in 3D surgery volume, domestic electrophysiology replacement acceleration
Microelectrophysiology (688351): Rich product layout, forward-looking, emerging in overseas markets, domestic electrophysiology leaders set sail
Microelectrophysiology (688351): Ice, fire, and electricity collaboratively lays out domestic leaders to accelerate the localization process of atrial fibrillation treatment
Microelectrophysiology (688351): The first quarter met expectations and is expected to accelerate quarterly
Microelectrophysiology (688351) Review Report: Accelerated Product Collection, Increased Product Approval, and Continued Entry into the Atrial Fibrillation Market
Microelectrophysiology (688351): A bright start to 1Q24 lays the tone for high annual growth
Microelectrophysiology (688351): 24Q1 performance exceeded expectations and the number of 3D surgeries increased rapidly
Dongfang Wealth Securities released a research report on April 24 stating that it gave Microelectronic Physiology (688351.SH) a purchase rating, and the target price was 29.58 yuan. The main reasons for the rating include: 1) leading domestic electrophysi
Dongfang Wealth Securities released a research report on April 16 stating that it gave Microelectronic Physiology (688351.SH) an increase in its holdings. The main reasons for the rating include: 1) rapid revenue growth and performance in line with expect
Microelectrophysiology-U (688351): The performance was in line with expectations and achieved a high increase in the number of surgeries
Microelectrophysiology (688351): Continued high revenue growth and accelerated release of new products
Pacific released a research report on April 8 stating that it gave Microelectrophysiology (688351.SH) a purchase rating. The main reasons for the rating include: 1) the featured product matrix provides a one-stop solution, and domestic and foreign markets
Microelectrophysiology (688351): 2023 performance is in line with expectations, optimistic about the company's 3D surgery volume, new products, and high overseas growth
Microelectrophysiology (688351): 23-year performance is in line with expectations, rapid increase in 3D surgery volume
Microelectrophysiology (688351): BETA+ individual stock ALPHA resonance in domestic and overseas two-wheel drive industries
Microelectrophysiology-U (688351): Steady growth with sufficient potential for long-term development
Microelectrophysiology-U (688351): Performance is in line with expectations, focus on the volume of core consumables for atrial fibrillation
Microelectrophysiology (688351): Rapid increase in surgical volume and gradual improvement of full energy layout
Microelectrophysiology (688351): Rapid domestic and foreign market expansion is expected to create a one-stop solution for “ice and thermal power”
Microelectrophysiology (688351): Co-layout of the three major energy platforms of “radiofrequency+freezing+pulsed electric field”, the company fully enters the atrial fibrillation market
Analysis
Price Target
No Data
